Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 6NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 4Lung Neoplasms 4Prostatic Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumors 3Urinary Bladder Neoplasms 2Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Head and Neck Neoplasms 2Biliary Tract Neoplasms 2Urothelial Cancer 1Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Part A and B: Advanced Solid Malignancies 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1

Interventions

Gemcitabine 27Cisplatin 24pembrolizumab 15durvalumab 12Fluorouracil 11Capecitabine 10Oxaliplatin 9Leucovorin 8Bevacizumab 7Carboplatin 5Paclitaxel 4Nivolumab 4Irinotecan 4Injections 4zanidatamab 3trametinib 3lenvatinib 3derazantinib 3atezolizumab 3Ramucirumab 3Docetaxel 3tremelimumab 2surufatinib 2pertuzumab 2gemcitabine-oxaliplatin regimen 2envafolimab 2Trastuzumab 2S 1 (combination) 2Itraconazole 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Biliary Tract Neoplasms × tremelimumab × Clear all
NCT01938612 2021-03-12

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
269 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
58 enrolled
BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡